Warp Drive Bio To Present On The Company’s First Program Using Its Small Molecule Assisted Receptor Targeting (SMART) Platform Against The RAS Oncogene At The AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer T

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Warp Drive Bio today announced that the company will present at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 6 to 9, 2015 at the Hynes Convention Center in Boston.

The presentation, “Drugging RAS Into Oblivion” will be given during the plenary session “Update on Targeting RAS and Cancer” on Saturday, November 7, 2015 between 10:20 a.m. – 12:20 p.m., by Greg Verdine, Ph.D., Founder, President and Chief Scientific Officer of Warp Drive Bio.

Help employers find you! Check out all the jobs and post your resume.

Back to news